Actos medicine is indicated for the treatment of type 2 diabetes in various types of patients with this disorder. Actos is proven to enhance glycemic control in patients. The system of proper dieting and regular physical are also included in the treatment.
The beneficial effect of the medicine is shown in the presence of insulin. Only patients with diabetes 2 type are indicated to use Actos. Patient with type 1 diabetes or diabetic ketoacidosis should not use this medicine.
The use of Actos in patients with hepatic impairment, severe or uncontrolled heart failure, bladder cancer is contraindicated.
Actos (pioglitazone) is an oral antidiabetic medication available in the dosages of 15, 30 or 45 mg. The medicine is active in the presence of insulin.
The mechanism of its action involves the feature of the medicine to reduce insulin resistance in the periphery and in the liver. It leads to release of more glucose which is insulin-dependent and degradation of hepatic glucose output.
Pioglitazone is not an agent which increases insulin secretion. It is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ).The receptors of PPAR are located in tissues important for insulin action including adipose tissue, skeletal muscle, and liver cells.
The medicine stimulates the receptors which contribute to the process of increasing glucose control and lipid metabolism.
The medicine is observed to reduce the hyperglycemia, hyperinsulinemia, and hypertriglyceridemia characteristic of insulin-resistant states. The alterations induced by the medicine promote higher responsiveness of insulin-dependent tissues.
Special hepatic tests should be conducted before and during the treatment with Actos. This will help to identify the actual liver function before and during the treatment.
The tests may include: serum alanine, aspartate aminotransferases, alkaline, phosphatase, total bilirubin and some other specific tests.
Monitoring liver function is recommended for patients who suffer from liver issues. For other people these tests are not suggested to be done. Patients with liver malfunction or abnormalities should be properly monitored during the treatment with Actos.